131-I-Metaiodobenzylguanidine Treatment of Malignant Phe

嗜铬细胞瘤是一种能够合成和分泌儿茶酚胺的嗜铬细胞肿瘤。本项目测试了~(131)I-间碘苯基胍(131I-MIBG)放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是测试了使用特定药物(即所谓的增敏剂)的预治疗是否增加了~(131)I-MIBG治疗在减少肿瘤大小和数量以及肿瘤负担方面的疗效。中心假设是，在恶性嗜铬细胞瘤患者中，131I-MIBG治疗可以摧毁肿瘤细胞，从而减少肿瘤的大小和数量，并减少肿瘤负担；而且，增敏程序增加了131I-MIBG的疗效。最近，FDA已经批准了该方案，密歇根大学获得131-I-MIBG用于治疗的合同也已获得批准。患者正被纳入这项研究。

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. Recently, the protocol has been approved by the FDA and the contract from the University of Michigan, to obtain 131-I-MIBG for treatment, has been approved. Patients are being enrolled into the study.